Expression and purification of recombinant tilapia lake virus segment 4 protein and its in-vitro biological activity for potential use in vaccine development

重组罗非鱼湖病毒4号片段蛋白的表达纯化及其体外生物活性研究,以期用于疫苗研发

阅读:2

Abstract

Tilapia lake virus (TiLV) disease is highly contagious and causes substantial mortality in tilapia. Currently, no effective treatments or commercial vaccines are available to prevent TiLV infection. In this study, TiLV segment 4 (S4) was cloned into the pET28a(+)vector and transformed into Escherichia coli BL21(DE3). Codon optimization was performed to enhance TiLV S4 protein expression, and a range of expression conditions were tested, including various inducers and postinduction temperatures and times for both soluble and insoluble protein expression. The recombinant TiLV S4 protein was purified using affinity chromatography. The optimal conditions for recombinant TiLV S4 expression were achieved via induction using 0.1 mM galactose at 37 °C for 1 h postinduction. The insoluble protein was denatured using 6 M urea and subsequently purified to yield a protein concentration of approximately 250 mg/L. Dot blot immunodetection assays confirmed consistent interactions between the purified TiLV S4 protein and the sera from infected fish and rabbit anti-TiLV antibodies. By identifying the optimal growth conditions and production factors for the recombinant protein, our study offers valuable information for the large-scale production of the TiLV S4 protein, which signals an important step forward in TiLV vaccine development.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。